Consecutive real-world treatment experience with a reduced starting dose of lenvatinib (14 mg) plus pembrolizumab for metastatic renal cell carcinoma
Although management of AEs was essential, early drug interruption was less frequent in our study compared with the CLEAR trial Japanese cohort. The response of a reduced starting dose of 14 mg lenvatinib for mRCC was almost the same as that in the CLEAR trial.
Authors
- Tomokazu Sazuka (ORCID: https://orcid.org/0000-0002-8902-7853)
- Manato Kanesaka
- Tomohiko Ichikawa (ORCID: https://orcid.org/0000-0002-8637-4163)
- Sangjon Pae
- Yusuke Imamura (ORCID: https://orcid.org/0009-0006-7207-1520)
- Kosuke Mikami
- Yasutaka Yamada (ORCID: https://orcid.org/0000-0002-0070-1590)
- Kentaro Murakami
- Keisuke Ando
- Yuki Iida (ORCID: https://orcid.org/0000-0001-9714-3013)
- Shinichi Sakamoto
- Shinpei Saito (ORCID: https://orcid.org/0000-0002-9346-0553)
- Kodai Sato (ORCID: https://orcid.org/0009-0003-7573-9547)
- Hiroshi Nihei
Institutions
- Chiba University (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-07-20
- DOI
- https://doi.org/10.1093/jjco/hyaf122
- Citations
- 2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.04